BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 19, 2011
View Archived Issues
Naftopidil has effects on stromal and cancer cells
Read More
New Wnt signaling inhibitors JW-74 and JW-67 inhibit tumor growth in vivo
Read More
New adenylate cyclase type 1 inhibitor NB-001 shows promise to treat neuropathic/inflammatory pain
Read More
Boehringer Ingelheim divulges new cannabinoid CB2 receptor agonists
Read More
BioCryst reports on phase III peramivir trials in influenza
Read More
Phase III data show benefits of Exparel after bunionectomy
Read More
PHD finger protein 6 is a tumor suppressor protein in AML
Read More
Vitae Pharma describes new 11-beta-HSD1 inhibitors
Read More
Adolor launches second phase II trial of ADL-5945 for opioid-induced constipation
Read More
New beta-secretase 1 inhibitors discovered at AstraZeneca
Read More
Cephalon patents new histamine H3 receptor antagonists/inverse agonists
Read More
Sirona Biochem reports on its sodium/glucose cotransporter 2 inhibitor for type 2 diabetes
Read More
Neovacs begins phase II TNF-K-005 trial of TNF-kinoid in Crohn's disease
Read More
Secondary endpoint met in phase III Corlux trial in Cushing's syndrome
Read More
Nabriva completes recruitment in phase II trial of BC-3781
Read More
Chugai grants Circadian Technologies global license to VEGF-D program
Read More
Abbott withdraws European MAA for Ozespa
Read More
Eli Lilly's Byetta is approved in Canada for type 2 diabetes
Read More
TransPharma Medical's ViaDerm becomes ViaDor
Read More
Phase III SUCCEED trial of oral ridaforolimus achieves primary endpoint
Read More
RG-7204 improves survival in phase III BRIM3 trial
Read More
Protalix provides update on programs in Gaucher's disease and Fabry's disease
Read More
Merck & Co. claims new inhibitors of Egl nine homolog 1, 2 and 3
Read More
New inhibitors discovered of polyamine transport into cancer cells
Read More
Astex Therapeutics begins first-in-human study of anticancer drug LEE-011
Read More